New article yahooooooooo
DIAGNOS Inc. Applying artificial intelligence in the diabetes market, a robust healthcare business has emerged. DIAGNOS Inc. (TSX-V: ADK) (US: DGNOF) (Frankfurt: 4D4) Share data, Capitalization, & Corporate info Shares Outstanding: 140,619,786 Fully Diluted: 196.8M (9.14M warrants, 10M options, 37M convertible) Recently Traded: ~CDN$0.15/share (TSX-V: ADK) 52 Week High/Low: $0.20 / 0.035 Current Market Capitalization: ~$21.1 million Canadian Corporate Website: www.DIAGNOS.ca DIAGNOS' share price is poised for significant upside revaluation as its vision loss prevention Computer Assisted Retinal Analysis (CARA) business targeting diabetics has, as of this fiscal Q3 (ending December-2016), turned profitable and its revenue growth curve is rapidly accelerating with no stop in sight. Able to cost effectively screen millions of diabetics; proprietary algorithms are capable of automatic detection of pathology in retinal images and lesion classification. Big Pharma now converting pilot programs to lucrative growing contracts for ADK.V (Novartis & Bayer are customers). ADK.V now positioned to target hospitals and clinics in USA. Governments are now starting to see the value in having ADK.V screen diabetic populations in order to contain costs.